NCT03132454View on ClinicalTrials.gov

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Recurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Palbociclib

Given PO

DRUG

Sorafenib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER